eftilagimod alfa – Patient Worthy

Eftilagimod Alfa Setback: Immutep Halts Landmark Lung Cancer Trial Following Futility Analysis

Post author:Bree Clare
Post published:March 26, 2026
Post category:non-small cell lung cancer

Immutep Limited has announced the discontinuation of TACTI-004, a pivotal Phase III clinical trial investigating eftilagimod alfa (efti) as a first-line treatment for advanced non-small cell lung cancer (NSCLC). According…

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More